Biotechnology company Circio Holding ASA (OSE:CRNA) and Entos Pharmaceuticals U.K. Ltd, a clinical-stage genetic medicines company, on Thursday announced a research collaboration to advance circular RNA delivery technology.
This partnership will combine Circio's circVec DNA vectors with Entos' Fusogenix PLV nucleic acid delivery platform.
The collaboration aims to improve delivery efficiency and reduce toxicity compared to lipid nanoparticle formulations. Entos will develop and validate PLV formulations of circVec DNA vectors and conduct in vivo testing.
Initial data is expected within three to six months. If successful, the results could support further development of novel, repeat-dosable therapeutic candidates for genetic medicine, chronic disease and vaccines.
Financial terms of the agreement were not disclosed.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA